Inactive Instrument

Other languages Neurometrix Inc Nasdaq

Equities

US6412553025

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	Apr. 19
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	Mar. 14
Ephraim Fields Discloses his Views on NeuroMetrix	Feb. 27
RS Fund Discloses its Views on NeuroMetrix	Feb. 26
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	Feb. 13
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	Dec. 12
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	Dec. 05
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	Nov. 20
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 20
NeuroMetrix Announces 1-for-8 Reverse Stock Split; Shares Fall	Nov. 20
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia	23-10-02
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-27
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia	23-07-11
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting	23-06-07
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-05-31
NeuroMetrix Reports 'Encouraging' Results of Chemotherapy-Induced Peripheral Neuropathy Clinical Trial	23-05-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Neurometrix Inc Nasdaq

Equities

US6412553025

Other languages

Filters